Carmel-based MBX Biosciences names Jeff Held as chief legal officer
MBX Biosciences announced Sept. 8, 2026 that Jeff Held, J.D., has been appointed Chief Legal Officer. The company also disclosed an inducement equity package that includes 89,250 stock options and 19,125 restricted stock units with multi-year vesting schedules.
MBX said Held brings over 30 years of legal, compliance and executive experience in biotechnology and healthcare. His recent role was Chief Legal Officer at Zenas BioPharma; earlier, as Senior Vice President and General Counsel at Deciphera Pharmaceuticals he helped lead more than $1 billion in equity financings and co-led Deciphera’s $2.4 billion sale to Ono Pharmaceutical.
MBX reported that, in connection with his appointment, the board approved an inducement award on Sept. 1, 2026 under Nasdaq Listing Rule 5635(c)(4). The grant comprises non-qualified options for 89,250 shares at an exercise price of $60.93 (Nasdaq close on Sept. 1, 2026) with a ten-year term and four-year vesting, plus 19,125 RSUs that vest 25% per year over four years.
Report a correction · Editorial standards · Our source directory
BusinessIndy examines this development and its implications for Indiana businesses and communities using the linked sources.
Continued verification is in progress.
Sources
Source date recorded as September 8, 2026 at 8:00 AM EDT. A sourced news brief; no independent staff reporting is implied. Prepared with AI assistance; source-dependent claims remain attributed in the article.
Related coverage
- IU Health’s Mosaic Center to add monthly orientations at 1776 N. Meridian St. to connect Indianapolis residents to healthcare jobs
- Indiana awards $13.1M GROW grant to Region 7 to expand rural healthcare services and workforce
- Indianapolis-based Eli Lilly reports Foundayo tied to modeled cuts in 10‑year diabetes and cardiovascular risk
Reader discussion
Join the discussion. Every comment is checked before publication. Community rules and appeals